Gabapentin gabapentin

The single largest commercial risk for gabapentin is not efficacy -- it is the widening gap between how prescribers frame discontinuation (easy, two-week taper) and what patients actually experience (weeks-to-months of disabling withdrawal), a trust-destroying moment that drives switching and fuels negative social narratives.

• Gabapentin earns a 7.1/10 rating across 2,613 Drugs.com reviews with 63% positive sentiment, driven by strong neuropathic and off-label pain relief, but cognitive side effects (brain fog, memory loss, aphasia) are the top reason patients self-discontinue.
• Withdrawal severity is the dominant negative narrative: patients consistently report that prescribers minimize or deny withdrawal risk, and actual taper experiences range from weeks to many months of vertigo, insomnia, anxiety, and skin hypersensitivity.
• Gabapentin is among the most broadly prescribed off-label drugs in the corpus -- anxiety, hot flashes, insomnia, fibromyalgia, migraines, and alcohol withdrawal -- creating a highly diverse, often undertreated patient population with unmet needs around dosing guidance and realistic expectations.
• An emerging drug-interaction anxiety signal is growing around gabapentin plus GLP-1 agonists (semaglutide, tirzepatide) and opioids/benzodiazepines, with a 2026 UCL study linking gabapentinoid plus benzodiazepine co-use to doubled drug-poisoning hospitalization risk, now circulating in patient forums.